Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8785275 | Brachytherapy | 2018 | 6 Pages |
Abstract
This is the first report of this cohort of patients treated with two-fraction HDR monotherapy. This regimen shows rates of toxicity and health-related quality of life that appear acceptable as compared to other treatment modalities. These results are also comparable with other reports with similar treatment regimens.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Marc Gaudet, Mathieu Pharand-Charbonneau, Marie-Pierre Desrosiers, Debbie Wright, Alain Haddad,